Available clinicogenomic characteristics of the four major KRASm tumor types (NSCLC, CRC, PDAC, endometrial) selected based on prevalence, incidence, and the landscape of KRAS inhibitor development, stratified by major KRAS isoforms, are shown in Table 1, and additional tumor types as well as pan-cancer analysis are described in Supplemental Table 4. This evidence concerns the gene KRAS and non-small cell lung carcinoma.